Orally-administrable supramolecular probiotic capsules enable cooperative colon-targeted inflammation inhibition for ameliorating ulcerative colitis

IF 9.6 1区 医学 Q1 ENGINEERING, BIOMEDICAL Acta Biomaterialia Pub Date : 2025-03-01 DOI:10.1016/j.actbio.2025.01.049
Ting Wang , Jie Chen , Chuandong Shu , Xinkun Shen , Yuanyuan Fu , Menghuan Li , Zhong Luo
{"title":"Orally-administrable supramolecular probiotic capsules enable cooperative colon-targeted inflammation inhibition for ameliorating ulcerative colitis","authors":"Ting Wang ,&nbsp;Jie Chen ,&nbsp;Chuandong Shu ,&nbsp;Xinkun Shen ,&nbsp;Yuanyuan Fu ,&nbsp;Menghuan Li ,&nbsp;Zhong Luo","doi":"10.1016/j.actbio.2025.01.049","DOIUrl":null,"url":null,"abstract":"<div><div>Ulcerative colitis (UC) is a prevalent gastrointestinal disease characterized by the chronical and refractory inflammation of colorectal mucosa and walls, which severely impairs overall well-being of individuals. Probiotics has shown tremendous promise for UC therapy due to its multifaceted mucosal barrier restoration and immunomodulation capabilities. Nevertheless, the successful administration of probiotics remains a clinical obstacle. Herein, we report a multifunctional supramolecular probiotic capsule based on clinically-tested biopolymers for UC therapy, which not only allow colon-targeted probiotic delivery via oral route but also enable concurrent delivery of hemostatic and anti-inflammatory drugs. Specifically, Clostridium butyricum (CB) was first engineered with protective norepinephrine (NE) coating and then encapsulated by self-assembled gelatin-based nanocomplexes modified with balsalazide and matrix metalloproteinase 2/9 (MMP2-/9)-responsive fibronectin peptides. The released balsalazide and fibronectin could induce rapid hemostasis and anti-inflammation actions to alleviate inflammation damage of the UC-affected colons in the short term, while CB could restore gut microbiota homeostasis to remodel intestinal immunocomposition and repair mucosal barrier for reducing UC risk in the long term. Overall, this study provides a promising option for UC treatment with good efficacy and minimal invasiveness.</div></div><div><h3>Statement of significance</h3><div>This study reports a supramolecular probiotic capsule with nanointegrative hemostatic and anti-inflammatory capacities for ulcerative colitis (UC) therapy, which could be orally administrated and activated in the inflamed colorectal sites. The probiotic capsules enable immediate UC symptom relief while also accelerating mucosal repair and preventing UC relapse in the long-term, offering an approach for UC treatment in the clinic.</div></div>","PeriodicalId":237,"journal":{"name":"Acta Biomaterialia","volume":"194 ","pages":"Pages 396-410"},"PeriodicalIF":9.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Biomaterialia","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1742706125000698","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Ulcerative colitis (UC) is a prevalent gastrointestinal disease characterized by the chronical and refractory inflammation of colorectal mucosa and walls, which severely impairs overall well-being of individuals. Probiotics has shown tremendous promise for UC therapy due to its multifaceted mucosal barrier restoration and immunomodulation capabilities. Nevertheless, the successful administration of probiotics remains a clinical obstacle. Herein, we report a multifunctional supramolecular probiotic capsule based on clinically-tested biopolymers for UC therapy, which not only allow colon-targeted probiotic delivery via oral route but also enable concurrent delivery of hemostatic and anti-inflammatory drugs. Specifically, Clostridium butyricum (CB) was first engineered with protective norepinephrine (NE) coating and then encapsulated by self-assembled gelatin-based nanocomplexes modified with balsalazide and matrix metalloproteinase 2/9 (MMP2-/9)-responsive fibronectin peptides. The released balsalazide and fibronectin could induce rapid hemostasis and anti-inflammation actions to alleviate inflammation damage of the UC-affected colons in the short term, while CB could restore gut microbiota homeostasis to remodel intestinal immunocomposition and repair mucosal barrier for reducing UC risk in the long term. Overall, this study provides a promising option for UC treatment with good efficacy and minimal invasiveness.

Statement of significance

This study reports a supramolecular probiotic capsule with nanointegrative hemostatic and anti-inflammatory capacities for ulcerative colitis (UC) therapy, which could be orally administrated and activated in the inflamed colorectal sites. The probiotic capsules enable immediate UC symptom relief while also accelerating mucosal repair and preventing UC relapse in the long-term, offering an approach for UC treatment in the clinic.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
口服给药的超分子益生菌胶囊能够协同结肠靶向炎症抑制改善溃疡性结肠炎。
溃疡性结肠炎(UC)是一种常见的胃肠道疾病,其特征是结肠粘膜和肠壁的慢性和难治性炎症,严重损害个体的整体健康。益生菌由于其多方面的粘膜屏障修复和免疫调节能力,在UC治疗中显示出巨大的希望。然而,益生菌的成功管理仍然是一个临床障碍。在此,我们报道了一种基于临床测试的生物聚合物的多功能超分子益生菌胶囊用于UC治疗,它不仅可以通过口服途径给药结肠靶向益生菌,还可以同时给药止血和抗炎药物。具体来说,首先用保护性的去甲肾上腺素(NE)涂层对丁酸梭菌(CB)进行修饰,然后用balsalazide和基质金属蛋白酶2/9 (MMP2-/9)响应纤维连接蛋白肽修饰的自组装明胶基纳米复合物对其进行封装。释放的balsalazide和纤维连接蛋白可诱导快速止血和抗炎作用,短期内减轻UC感染结肠的炎症损伤,而CB可恢复肠道菌群稳态,重塑肠道免疫组成,修复粘膜屏障,长期降低UC风险。总的来说,这项研究为UC治疗提供了一个有希望的选择,具有良好的疗效和最小的侵入性。意义声明:本研究报道了一种具有纳米整合止血和抗炎能力的超分子益生菌胶囊,可用于溃疡性结肠炎(UC)治疗,该胶囊可口服并在发炎的结直肠部位激活。益生菌胶囊可以立即缓解UC症状,同时加速粘膜修复,防止UC长期复发,为UC的临床治疗提供了一种途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
阿拉丁
N‐hydroxy succinimide (NHS)
阿拉丁
amino-Cyanine5 (Cy5)
阿拉丁
1-(3-dimethylamino propyl)?3-ethyl carbodiimide hydrochloride (EDC)
来源期刊
Acta Biomaterialia
Acta Biomaterialia 工程技术-材料科学:生物材料
CiteScore
16.80
自引率
3.10%
发文量
776
审稿时长
30 days
期刊介绍: Acta Biomaterialia is a monthly peer-reviewed scientific journal published by Elsevier. The journal was established in January 2005. The editor-in-chief is W.R. Wagner (University of Pittsburgh). The journal covers research in biomaterials science, including the interrelationship of biomaterial structure and function from macroscale to nanoscale. Topical coverage includes biomedical and biocompatible materials.
期刊最新文献
Editorial Board A latent TGF-β conjugated scaffold improves neocartilage development Calcification and structural damage together accelerate porcine pericardium failure Axially loaded whole teeth of Atlantic wolffish exhibit negative Poisson’s ratios due to their osteodentin microarchitecture A physiological oxygen gradient liver-zonation-on-a-chip reveals HIF-2α intervention in hepatic lipotoxicity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1